ME02662B - Niskofrekventna terapija glatiramer acetatom - Google Patents
Niskofrekventna terapija glatiramer acetatomInfo
- Publication number
- ME02662B ME02662B MEP-2017-17A MEP1717A ME02662B ME 02662 B ME02662 B ME 02662B ME P1717 A MEP1717 A ME P1717A ME 02662 B ME02662 B ME 02662B
- Authority
- ME
- Montenegro
- Prior art keywords
- glatiramer acetate
- treatment
- multiple sclerosis
- subcutaneous injections
- reaction
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims 9
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims 9
- 229960003776 glatiramer acetate Drugs 0.000 title claims 9
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 239000007929 subcutaneous injection Substances 0.000 claims 4
- 238000010254 subcutaneous injection Methods 0.000 claims 4
- 229940126601 medicinal product Drugs 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Claims (4)
1. Glatiramer acetat za upotrebu u režimu od tri potkožne injekcije doze od 40 mg glatiramer acetata na svakih sedam dana, sa najmanje jednim danom između svake dve uzastopne potkožne injekcije, za upotrebu u lečenju pacijenta koji pati od relapsno-remitentne multiple skleroze ili koji je doživeo prvi klinički napad i koji je pod visokim rizikom od razvoja klinički definitivne multiple skleroze, i gde navedeni farmaceutski preparat dalje sadrži manitol.
2. Medikament koji sadrži glatiramer acetat za upotrebu u lečenju pacijenta koji pati od relapsno-remitentne multiple skleroze ili koji je doživeo prvi klinički napad i koji je pod visokim rizikom od razvoja klinički definitivne multiple skleroze, naznačen time što se navedeni medikament primenjuje u režimu od tri potkožne injekcije doze od 40 mg glatiramer acetata na svakih sedam dana, pri čemu je između dve uzastopne potkožne injekcije najmanje jedan dan, i gde navedeni farmaceutski preparat dalje sadrži manitol.
3. Glatiramer acetat za upotrebu prema patentnom zahtevu 1, naznačen time što je podnošljivost tretmana glatiramer acetatom kod pacijenta - čoveka povećana time što je smanjena učestalost trenutne reakcije nakon injekcije ili reakcije na mestu injekcije.
4. Medikament koji sadrži glatiramer acetat za upotrebu prema patentnom zahtevu 2, naznačen time što je podnošljivost tretmana glatiramer acetatom kod pacijenta - čoveka povećana time što je smanjena učestalost trenutne reakcije neposredno nakon injekcije ili reakcije na mestu injekcije. 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27468709P | 2009-08-20 | 2009-08-20 | |
| US33761210P | 2010-02-11 | 2010-02-11 | |
| EP15171065.4A EP2949335B1 (en) | 2009-08-20 | 2010-08-19 | Low frequency glatiramer acetate therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02662B true ME02662B (me) | 2017-06-20 |
Family
ID=43605835
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2013-81A ME01536B (me) | 2009-08-20 | 2010-08-19 | Niskofrekventna terapija glatiramer acetatom |
| MEP-2017-17A ME02662B (me) | 2009-08-20 | 2010-08-19 | Niskofrekventna terapija glatiramer acetatom |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2013-81A ME01536B (me) | 2009-08-20 | 2010-08-19 | Niskofrekventna terapija glatiramer acetatom |
Country Status (34)
| Country | Link |
|---|---|
| US (15) | US8399413B2 (me) |
| EP (5) | EP2630962B1 (me) |
| JP (3) | JP6038653B2 (me) |
| KR (4) | KR20170123354A (me) |
| CN (3) | CN102625657A (me) |
| AR (2) | AR077896A1 (me) |
| AT (1) | AT15421U1 (me) |
| AU (1) | AU2010284666B2 (me) |
| BR (1) | BR112012003730A2 (me) |
| CA (2) | CA2760802C (me) |
| CY (2) | CY1114537T1 (me) |
| CZ (2) | CZ29723U1 (me) |
| DE (1) | DE202010018377U1 (me) |
| DK (5) | DK2405749T3 (me) |
| EA (3) | EA019998B9 (me) |
| ES (4) | ES2612001T4 (me) |
| HK (2) | HK1258008A1 (me) |
| HR (4) | HRP20130677T1 (me) |
| HU (2) | HUE039335T2 (me) |
| IL (3) | IL218106A0 (me) |
| LT (3) | LT3199172T (me) |
| ME (2) | ME01536B (me) |
| MX (1) | MX2012002082A (me) |
| NZ (1) | NZ598661A (me) |
| PL (4) | PL2405749T3 (me) |
| PT (4) | PT2630962T (me) |
| RS (2) | RS52885B (me) |
| SG (2) | SG10201405806SA (me) |
| SI (4) | SI2949335T1 (me) |
| SK (1) | SK501352015U1 (me) |
| SM (2) | SMT201700057T1 (me) |
| TW (3) | TW201733575A (me) |
| UA (1) | UA103699C2 (me) |
| WO (1) | WO2011022063A1 (me) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US8077333B2 (en) * | 2002-09-09 | 2011-12-13 | Canon Kabushiki Kaisha | Printing control apparatus and printing control method |
| SI2949335T1 (sl) | 2009-08-20 | 2017-05-31 | Yeda Research & Development Company, Ltd. | Nizkofrekventna terapija z glatiramer acetatom |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定 |
| EP2906719A4 (en) | 2012-10-10 | 2016-11-09 | Teva Pharma | PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE |
| WO2014107533A2 (en) * | 2013-01-04 | 2014-07-10 | Teva Pharmaceutical Industries Ltd. | Characterizing a glatiramer acetate related drug product |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CN103641897B (zh) * | 2013-11-27 | 2017-01-04 | 深圳翰宇药业股份有限公司 | 一种合成醋酸格拉替雷的方法 |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| WO2015195605A1 (en) * | 2014-06-17 | 2015-12-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of glatiramer acetate by oral patches |
| CN104844697B (zh) * | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | 醋酸格拉替雷的制备方法 |
| US9155775B1 (en) * | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HRP20250396T1 (hr) | 2016-08-31 | 2025-05-23 | Mapi Pharma Ltd. | Depo sustavi koji sadrže glatiramer acetat |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
| KR102519053B1 (ko) | 2021-02-08 | 2023-04-06 | 건국대학교 산학협력단 | 염산가스의 농도 측정을 위한 수분 전처리 시스템 |
| KR102519054B1 (ko) | 2021-03-12 | 2023-04-06 | 건국대학교 산학협력단 | 나피온 드라이어와 수분 전처리장치의 결합시스템 |
| CA3220684A1 (en) | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
| WO2023062511A1 (en) * | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| EP0219899B1 (en) | 1985-10-11 | 1990-08-08 | Duphar International Research B.V | Automatic injector |
| US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6454746B1 (en) | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| AU757413B2 (en) | 1998-09-25 | 2003-02-20 | Yeda Research And Development Co. Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| CA2355400A1 (en) | 1998-11-12 | 2000-05-18 | Yeda Research And Development Co., Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
| EP2111870A1 (en) | 1999-08-27 | 2009-10-28 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| DK1248643T3 (da) | 2000-01-20 | 2005-11-07 | Yeda Res & Dev | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| MXPA02008023A (es) | 2000-02-18 | 2005-06-30 | Yeda Res & Dev | Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar. |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| AU7528001A (en) | 2000-06-05 | 2001-12-17 | Teva Pharma | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20020037848A1 (en) | 2000-06-07 | 2002-03-28 | Michal Eisenbach-Schwartz | Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| WO2004043995A2 (en) | 2002-11-13 | 2004-05-27 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| JP2006507061A (ja) | 2002-11-25 | 2006-03-02 | テクファーマ・ライセンシング・アクチェンゲゼルシャフト | リセット可能な解放安全装置を有する自動注射装置 |
| US7274347B2 (en) | 2003-06-27 | 2007-09-25 | Texas Instruments Incorporated | Prevention of charge accumulation in micromirror devices through bias inversion |
| NZ569331A (en) | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| EP1603530A1 (en) | 2003-03-04 | 2005-12-14 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| CA2525771A1 (en) * | 2003-05-14 | 2004-12-02 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| EA200600877A1 (ru) | 2003-10-31 | 2006-12-29 | Тева Фармасьютикал Индастриз, Лтд. | Наночастицы для доставки лекарств |
| HUP0303779A2 (en) * | 2003-11-20 | 2006-02-28 | Richter Gedeon Vegyeszet | Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex |
| AU2005218625A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| BRPI0509164A (pt) * | 2004-03-25 | 2007-09-11 | Janssen Pharmaceutica Nv | compostos de imidazol |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| KR20070036062A (ko) | 2004-05-07 | 2007-04-02 | 펩팀문, 인코포레이티드 | 랜덤 공중합체에 의해 질병을 치료하는 방법 |
| EP1761276B1 (en) * | 2004-06-25 | 2013-07-24 | ID Biomedical Corporation of Quebec | Compositions and methods for treating neurological disorders |
| EP1796710A4 (en) | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
| PL1797109T3 (pl) | 2004-09-09 | 2016-11-30 | Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania | |
| ES2338138T3 (es) | 2004-09-09 | 2010-05-04 | Teva Pharmaceutical Industries Ltd | Proceso para la preparacion de mezclas de polipeptidos utilizando acido bromhidrico purificado. |
| AR052321A1 (es) | 2004-10-29 | 2007-03-14 | Sandoz Ag | Procesos para la preparacion de un polipeptido |
| EP1838326A4 (en) | 2005-02-02 | 2009-09-30 | Teva Pharma | PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2596664A1 (en) | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| EP1891233A4 (en) | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) * | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| KR101440795B1 (ko) | 2006-06-30 | 2014-09-22 | 애브비 바이오테크놀로지 리미티드 | 자동 주사 장치 |
| WO2008006026A1 (en) | 2006-07-05 | 2008-01-10 | Momenta Pharmaceuticals, Inc. | Improved process for the preparation of copolymer-1 |
| US20110123482A1 (en) * | 2007-10-01 | 2011-05-26 | The Johns Hopkins University | Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide |
| EP2111105A4 (en) | 2007-11-28 | 2011-05-04 | METHOD FOR DELAYING THE BEGINNING OF A CLINICALLY DEFINED CLINIC SCLEROSIS | |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| ATE549013T1 (de) | 2009-07-15 | 2012-03-15 | Teva Pharma | Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren |
| SI2949335T1 (sl) | 2009-08-20 | 2017-05-31 | Yeda Research & Development Company, Ltd. | Nizkofrekventna terapija z glatiramer acetatom |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定 |
| EP2906719A4 (en) | 2012-10-10 | 2016-11-09 | Teva Pharma | PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE |
| WO2014107533A2 (en) | 2013-01-04 | 2014-07-10 | Teva Pharmaceutical Industries Ltd. | Characterizing a glatiramer acetate related drug product |
| EP2968559A4 (en) | 2013-03-12 | 2016-11-02 | Teva Pharma | RITUXIMAB INDUCTION THERAPY FOLLOWED BY GLATIRAMERACETATE THERAPY |
-
2010
- 2010-08-19 SI SI201031375A patent/SI2949335T1/sl unknown
- 2010-08-19 KR KR1020177031069A patent/KR20170123354A/ko not_active Ceased
- 2010-08-19 ES ES15171065.4T patent/ES2612001T4/es active Active
- 2010-08-19 PL PL10810282T patent/PL2405749T3/pl unknown
- 2010-08-19 BR BR112012003730-7A patent/BR112012003730A2/pt not_active Application Discontinuation
- 2010-08-19 EP EP13166080.5A patent/EP2630962B1/en not_active Revoked
- 2010-08-19 DK DK10810282.3T patent/DK2405749T3/da active
- 2010-08-19 CZ CZ2015-31885U patent/CZ29723U1/cs not_active IP Right Cessation
- 2010-08-19 EP EP15171065.4A patent/EP2949335B1/en not_active Revoked
- 2010-08-19 CN CN2010800369660A patent/CN102625657A/zh active Pending
- 2010-08-19 KR KR1020167006001A patent/KR20160038057A/ko not_active Ceased
- 2010-08-19 EA EA201270292A patent/EA019998B9/ru not_active IP Right Cessation
- 2010-08-19 PL PL17157735T patent/PL3199172T3/pl unknown
- 2010-08-19 ME MEP-2013-81A patent/ME01536B/me unknown
- 2010-08-19 ES ES13166080.5T patent/ES2688873T3/es active Active
- 2010-08-19 US US12/806,684 patent/US8399413B2/en not_active Expired - Fee Related
- 2010-08-19 SG SG10201405806SA patent/SG10201405806SA/en unknown
- 2010-08-19 NZ NZ598661A patent/NZ598661A/xx unknown
- 2010-08-19 EA EA201400394A patent/EA032283B1/ru unknown
- 2010-08-19 EP EP17157735.6A patent/EP3199172B1/en not_active Revoked
- 2010-08-19 WO PCT/US2010/002283 patent/WO2011022063A1/en not_active Ceased
- 2010-08-19 SM SM20170057T patent/SMT201700057T1/it unknown
- 2010-08-19 PL PL13166080T patent/PL2630962T3/pl unknown
- 2010-08-19 AU AU2010284666A patent/AU2010284666B2/en not_active Withdrawn - After Issue
- 2010-08-19 UA UAA201203259A patent/UA103699C2/ru unknown
- 2010-08-19 DK DK15171065.4T patent/DK2949335T3/en active
- 2010-08-19 DK DK13166080.5T patent/DK2630962T3/en active
- 2010-08-19 DK DK17157735.6T patent/DK3199172T3/en active
- 2010-08-19 DE DE202010018377.4U patent/DE202010018377U1/de not_active Ceased
- 2010-08-19 SI SI201031740T patent/SI3199172T1/sl unknown
- 2010-08-19 PT PT131660805T patent/PT2630962T/pt unknown
- 2010-08-19 RS RS20130293A patent/RS52885B/sr unknown
- 2010-08-19 SG SG2012011425A patent/SG178495A1/en unknown
- 2010-08-19 PT PT17157735T patent/PT3199172T/pt unknown
- 2010-08-19 CZ CZ2016-33036U patent/CZ30474U1/cs not_active IP Right Cessation
- 2010-08-19 PT PT151710654T patent/PT2949335T/pt unknown
- 2010-08-19 ES ES17157735.6T patent/ES2689711T3/es active Active
- 2010-08-19 SI SI201031719T patent/SI2630962T1/sl unknown
- 2010-08-19 ME MEP-2017-17A patent/ME02662B/me unknown
- 2010-08-19 PL PL15171065T patent/PL2949335T3/pl unknown
- 2010-08-19 CN CN201610104429.4A patent/CN105770855A/zh active Pending
- 2010-08-19 AT ATGM50231/2015U patent/AT15421U1/de not_active IP Right Cessation
- 2010-08-19 KR KR1020147012452A patent/KR20140061559A/ko not_active Ceased
- 2010-08-19 LT LTEP17157735.6T patent/LT3199172T/lt unknown
- 2010-08-19 HU HUE17157735A patent/HUE039335T2/hu unknown
- 2010-08-19 JP JP2012525530A patent/JP6038653B2/ja active Active
- 2010-08-19 KR KR1020127007115A patent/KR20120090044A/ko not_active Ceased
- 2010-08-19 ES ES10810282T patent/ES2424692T3/es active Active
- 2010-08-19 RS RS20170053A patent/RS55607B1/sr unknown
- 2010-08-19 CA CA2760802A patent/CA2760802C/en active Active
- 2010-08-19 CN CN201610878988.0A patent/CN107050423A/zh active Pending
- 2010-08-19 LT LTEP13166080.5T patent/LT2630962T/lt unknown
- 2010-08-19 LT LTEP15171065.4T patent/LT2949335T/lt unknown
- 2010-08-19 HR HRP20130677AT patent/HRP20130677T1/hr unknown
- 2010-08-19 SI SI201030270T patent/SI2405749T1/sl unknown
- 2010-08-19 MX MX2012002082A patent/MX2012002082A/es active IP Right Grant
- 2010-08-19 CA CA2876966A patent/CA2876966A1/en not_active Abandoned
- 2010-08-19 PT PT108102823T patent/PT2405749E/pt unknown
- 2010-08-19 EA EA201691347A patent/EA032287B1/ru unknown
- 2010-08-19 EP EP18179172.4A patent/EP3409286B1/en not_active Revoked
- 2010-08-19 HU HUE15171065A patent/HUE031282T2/hu unknown
- 2010-08-19 EP EP10810282.3A patent/EP2405749B1/en not_active Revoked
- 2010-08-20 TW TW106100768A patent/TW201733575A/zh unknown
- 2010-08-20 TW TW099128023A patent/TWI477273B/zh active
- 2010-08-20 AR ARP100103062A patent/AR077896A1/es not_active Application Discontinuation
- 2010-08-20 TW TW103138861A patent/TWI643614B/zh not_active IP Right Cessation
-
2011
- 2011-11-30 US US13/308,299 patent/US8232250B2/en not_active Expired - Fee Related
-
2012
- 2012-02-14 IL IL218106A patent/IL218106A0/en active IP Right Grant
-
2013
- 2013-02-19 US US13/770,677 patent/US8969302B2/en not_active Expired - Fee Related
- 2013-07-22 CY CY20131100615T patent/CY1114537T1/el unknown
-
2014
- 2014-02-26 HK HK19100376.3A patent/HK1258008A1/en unknown
- 2014-06-30 IL IL233468A patent/IL233468A0/en unknown
-
2015
- 2015-01-12 AR ARP150100073A patent/AR099078A2/es not_active Application Discontinuation
- 2015-02-24 US US14/630,326 patent/US20150164977A1/en not_active Abandoned
- 2015-03-30 US US14/673,257 patent/US9402874B2/en active Active
- 2015-05-13 JP JP2015098415A patent/JP6169644B2/ja active Active
- 2015-05-22 US US14/720,556 patent/US9155776B2/en not_active Expired - Fee Related
- 2015-12-18 SK SK50135-2015U patent/SK501352015U1/sk unknown
-
2016
- 2016-01-06 DK DK201600003U patent/DK201600003Y3/da not_active IP Right Cessation
- 2016-05-06 US US15/148,215 patent/US20160250251A1/en not_active Abandoned
- 2016-12-01 HK HK16113727.5A patent/HK1225310A1/zh unknown
- 2016-12-15 US US15/380,579 patent/US20170095523A1/en not_active Abandoned
-
2017
- 2017-01-13 HR HRP20170056TT patent/HRP20170056T2/hr unknown
- 2017-01-16 CY CY20171100052T patent/CY1118529T1/el unknown
- 2017-01-25 SM SM201700057T patent/SMT201700057B/it unknown
- 2017-02-22 JP JP2017031335A patent/JP2017132773A/ja not_active Withdrawn
- 2017-03-27 US US15/469,758 patent/US20170196803A1/en not_active Abandoned
- 2017-04-26 IL IL251943A patent/IL251943A0/en unknown
- 2017-07-05 US US15/642,201 patent/US20170296464A1/en not_active Abandoned
- 2017-11-13 US US15/811,495 patent/US20180064639A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/908,441 patent/US20180185274A1/en not_active Abandoned
- 2018-06-27 US US16/020,591 patent/US20180311149A1/en not_active Abandoned
- 2018-08-06 HR HRP20181253TT patent/HRP20181253T1/hr unknown
- 2018-08-06 HR HRP20181254TT patent/HRP20181254T1/hr unknown
- 2018-10-19 US US16/165,541 patent/US20190054013A1/en not_active Abandoned
-
2019
- 2019-02-11 US US16/272,786 patent/US20190175494A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| Ma et al. | Traditional Chinese medicine combined with hepatic targeted drug delivery systems: A new strategy for the treatment of liver diseases | |
| BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
| HRP20120349T1 (hr) | Formulacija glatiramer acetata smanjenog volumenai postupci davanja | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| JP2016204396A5 (me) | ||
| NZ807894A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| JP2015187125A5 (me) | ||
| WO2009021521A3 (en) | Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
| RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
| JP2013541583A5 (me) | ||
| BRPI0804623B8 (pt) | uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos | |
| JP2007238598A5 (me) | ||
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| JP2017508455A5 (me) | ||
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| NZ597675A (en) | Medicament for the long term nsaid use | |
| JP2010519274A5 (me) | ||
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
| CN106727610A (zh) | 一种治疗病毒性心肌炎的西药组合物及其应用 | |
| NZ767902B2 (en) | Methods of treating ulcerative colitis |